Twist Bioscience Corporation Common Stock (TWST) is a publicly traded Healthcare sector company. As of May 21, 2026, TWST trades at $54.23 with a market cap of $3.10B and a P/E ratio of -40.03. TWST moved +8.46% today. Year to date, TWST is +56.26%; over the trailing twelve months it is +73.60%. Its 52-week range spans $23.30 to $66.06. Analyst consensus is strong buy with an average price target of $63.43. Rallies surfaces TWST's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Twist Bioscience Posts 13th Straight Growth, Sees 28% DNA and 55% Therapeutics Gains: Twist Bioscience delivered its 13th straight quarter of sequential revenue growth, led by 28% expansion in DNA Synthesis and Protein Solutions from AI-driven drug discovery investments. Therapeutics revenue surged 55%, while NGS uptake in MRD oncology diagnostics reaccelerated through faster panel customization and heightened sensitivity.
| Metric | Value |
|---|---|
| Price | $54.23 |
| Market Cap | $3.10B |
| P/E Ratio | -40.03 |
| EPS | $-1.32 |
| Dividend Yield | 0.00% |
| 52-Week High | $66.06 |
| 52-Week Low | $23.30 |
| Volume | 512 |
| Avg Volume | 0 |
| Revenue (TTM) | $409.48M |
| Net Income | $-81.28M |
| Gross Margin | 52.07% |
7 analysts cover TWST: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $63.43.